<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02906943</url>
  </required_header>
  <id_info>
    <org_study_id>OCTANE</org_study_id>
    <nct_id>NCT02906943</nct_id>
  </id_info>
  <brief_title>Ontario-wide Cancer TArgeted Nucleic Acid Evaluation</brief_title>
  <acronym>OCTANE</acronym>
  <official_title>Ontario-wide Cancer TArgeted Nucleic Acid Evaluation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Princess Margaret Hospital, Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Substantial progress has been made in the treatment of cancer through the use of targeted&#xD;
      therapies, but what works for one patient might not work for another patient. Certain drugs&#xD;
      are now being developed that target specific molecules in the body that are believed to be&#xD;
      part of the disease.&#xD;
&#xD;
      Biomarkers are specific characteristics of the cancer that may help provide prognostic&#xD;
      information (e.g. how well patients will be regardless of the treatments given) or help&#xD;
      predict sensitivity or resistance to a specific treatment.&#xD;
&#xD;
      The study will collect archival tumor samples (previously collected biopsy or surgical tumor&#xD;
      samples) to provide biomarker data about a patient's cancer, which may help their physicians&#xD;
      to identify which clinical trials of new drug treatments may be most appropriate for the&#xD;
      patient in the future and may also guide the use of approved treatments that may potentially&#xD;
      benefit the patient.&#xD;
&#xD;
      Another goal of this study is to develop a province-wide registry of targeted gene sequencing&#xD;
      testing results that will be made available to cancer researchers. Additional tumour tissue&#xD;
      and blood samples collected from all study participants will also be stored in a biobank at&#xD;
      the Ontario Institute for Cancer Research for future research.&#xD;
&#xD;
      The study will also look at linking data from this study to other health care databases to&#xD;
      further collect information about the health care the patients received, including medical&#xD;
      tests, clinic visits, or procedures both before and after participating in this study. Having&#xD;
      more information about patient health to relate to the DNA sequences may provide new insights&#xD;
      into cancer and its treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A recent survey of clinical genetic testing laboratories for cancer diagnostics by the&#xD;
      Molecular Oncology Advisory Committee for Cancer Care Ontario identified disparities in&#xD;
      access and use patterns for next generation sequencing (NGS) across the province of Ontario.&#xD;
      All fourteen responding laboratories indicated that NGS instruments were either currently&#xD;
      being used for clinical testing, were in the validation stage, or that they were planning to&#xD;
      purchase NGS instruments within the near future. Respondents were uncertain about what tests&#xD;
      should be performed, how costing and reimbursement would be addressed by the provincial&#xD;
      funding agency (e.g. individual tests vs. panels), and how to deal with informatics issues&#xD;
      from NGS testing, such as storage, variant interpretation, and utilization over the long&#xD;
      term.&#xD;
&#xD;
      Given the increasing use of multi-gene somatic mutation testing in routine clinical cancer&#xD;
      care (e.g. KRAS, NRAS, BRAF mutations in colorectal cancer, EGFR mutation and ALK&#xD;
      translocation in non-small cell lung cancer, and BRAF, NRAS, and cKIT mutations in malignant&#xD;
      melanoma), there is a need to expand the infrastructure for NGS panel testing in clinical&#xD;
      laboratories. With a single payer provincial health care system, there is also an opportunity&#xD;
      to develop a provincial-wide registry of NGS panel-based testing results and repository of&#xD;
      genomically-characterized and clinically-annotated tumor tissues and blood samples to&#xD;
      accelerate the development of additional &quot;omic&quot;-based tests for clinical use.&#xD;
&#xD;
      This study will enroll patients with advanced, incurable solid tumors at selected Ontario&#xD;
      hospitals receiving standard palliative treatment(s). Archival formalin-fixed paraffin&#xD;
      embedded (FFPE) tumor tissue will be requested and undergo targeted panel sequencing. An&#xD;
      additional FFPE tissue sample will be requested at the same time for future research&#xD;
      purposes. Patients will also be asked to provide blood samples for future research. A&#xD;
      selected number of genes will be annotated in a research report provided to their treating&#xD;
      oncologist. In addition to the clinically reported variants, targeted NGS testing results for&#xD;
      all tested genes will be captured in a clinical research database that can be accessed by the&#xD;
      treating oncologist in a secure web-based portal.&#xD;
&#xD;
      Following the reporting of targeted DNA sequencing results into the web-portal, remaining&#xD;
      tumor DNA will be stored in the clinical testing laboratories. Blood samples collected at the&#xD;
      time of consent and additional FFPE research blocks or slides collected for research will be&#xD;
      transferred to a centralized biorepository maintained by the Ontario Tumour Bank (OTB) for&#xD;
      more comprehensive analysis at the Princess Margaret (PM)-Ontario Institute for Cancer&#xD;
      Research (OICR) Translational Genomics Laboratory (TGL). Blood will undergo standard germline&#xD;
      DNA extraction and plasma processing for future circulating tumor DNA (ctDNA) and RNA (ctRNA)&#xD;
      isolation at the PM-OICR TGL. Selected patient samples will be further characterized at the&#xD;
      PM-OICR TGL for test development, additional sequencing, or discovery research.&#xD;
&#xD;
      All patients will be asked to provide permission for data-sharing with other cancer&#xD;
      researchers. The consent will also include a provision for review of patient health records&#xD;
      through review of patient charts or administrative databases (i.e. Cancer Care Ontario New&#xD;
      Drug Funding Program, Provincial Cancer Registry, etc.) to obtain addition information about&#xD;
      time on drug treatments and survival.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients included in a province-wide registry of NGS panel-based testing results</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in use of NGS panel-based testing in Ontario clinical genetic testing laboratories</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients included in province-wide repository of genomically-characterized tumour tissue and blood samples and their utilization rates for future research</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in rates of genomics based clinical research in Ontario</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Utilization rates of province-wide genomically-characterized and clinically-annotated patient base in enrollment into specific research initiatives</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Utilization rates of molecular profiling information provided to treating physicians in guiding future treatment decisions</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of successful linkages between transferred study data and administrative databases</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concordance between administrative data and clinically abstracted data comparing variables using 2x2 concordance tables</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">10000</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Lung Cancer</condition>
  <condition>Colorectal Cancer</condition>
  <condition>Melanoma</condition>
  <condition>Gynecological Cancer</condition>
  <condition>Genitourinary Cancer</condition>
  <condition>Pancreatobiliary Cancer</condition>
  <condition>Gastrointestinal Cancer</condition>
  <condition>Head and Neck Cancer</condition>
  <condition>Rare Cancer</condition>
  <condition>Unknown Primary Cancer</condition>
  <arm_group>
    <arm_group_label>Advanced cancer</arm_group_label>
    <description>Patients with advanced, incurable solid tumors receiving standard palliative treatment(s) will have archival tumor specimens requested and used for targeted next generation sequencing (NGS) testing. Blood samples and additional archival tumor specimens will be collected for banking and future research purposes.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Archival tumor tissue 2 tubes of whole blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Advanced solid tumor malignancies, where archived formalin-fixed paraffin embedded (FFPE)&#xD;
        is available and adequate for molecular profiling.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with histological confirmation of advanced solid tumor malignancies who are&#xD;
             candidates for systemic therapy.&#xD;
&#xD;
          2. All patients must have sufficient FFPE archived tumor tissue for molecular profiling.&#xD;
&#xD;
          3. Patient must be â‰¥ 18 years old.&#xD;
&#xD;
          4. Patient's ECOG performance status equal to 0 or 1.&#xD;
&#xD;
          5. All patients must have a life expectancy of &gt; 6 months.&#xD;
&#xD;
          6. All patients must have adequate organ functions.&#xD;
&#xD;
          7. All patients must have signed and dated an informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        1. Patients must not have received more than 2 lines of prior cytotoxic therapy for their&#xD;
        recurrent/metastatic disease, with the exception of Phase I trial candidates who will not&#xD;
        be excluded if more than 2 lines of prior cytotoxic therapy have been received.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philippe Bedard, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Princess Margaret Hospital, Canada</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lillian Siu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Princess Margaret Hospital, Canada</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Samanta Del Rossi</last_name>
    <phone>416-946-4501</phone>
    <phone_ext>3486</phone_ext>
    <email>samanta.delrossi@uhn.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Juravinski Cancer Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kingston General Hospital</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital Cancer Centre</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Han (Jenny) Zhang</last_name>
      <phone>613-737-7700</phone>
      <phone_ext>77265</phone_ext>
      <email>hanzhang@ohri.ca</email>
    </contact>
    <contact_backup>
      <last_name>Kendra Christink</last_name>
      <phone>613-737-7700</phone>
      <phone_ext>70308</phone_ext>
      <email>kchristink@toh.ca</email>
    </contact_backup>
    <investigator>
      <last_name>John Hilton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samanta Del Rossi</last_name>
      <phone>416-946-4501</phone>
      <phone_ext>2642</phone_ext>
      <email>samanta.delrossi@uhn.ca</email>
    </contact>
    <investigator>
      <last_name>Philippe Bedard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lillian Siu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>September 9, 2016</study_first_submitted>
  <study_first_submitted_qc>September 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2016</study_first_posted>
  <last_update_submitted>January 21, 2021</last_update_submitted>
  <last_update_submitted_qc>January 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Molecular Profiling</keyword>
  <keyword>Advanced Cancer</keyword>
  <keyword>Advanced Solid Tumors</keyword>
  <keyword>Phase I Clinical Trial Candidates</keyword>
  <keyword>Next Generation Sequencing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastrointestinal Neoplasms</mesh_term>
    <mesh_term>Urogenital Neoplasms</mesh_term>
    <mesh_term>Neoplasms, Unknown Primary</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Targeted gene sequencing results, along with limited clinical information that does not identify the patient as an individual, such as age, partial date of birth (year, month), gender, cancer type, and pathology information related to the samples tested, and survival time will be sent to centralized scientific databases or shared with collaborating researchers.&#xD;
Data from this study can be shared through two types of databases: open-access or controlled-access. An open-access database is publicly accessible and contains limited clinical information and analyses of samples. A controlled-access database contains more detailed clinical information, such as relevant past medical history and the results of prior and ongoing cancer treatments, and analyses of samples, but is only accessible to researchers who sign agreements defining how data may be used. All data will be stripped of all personal identifying information.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

